De novo thrombotic microangiopathy after kidney transplantation

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →

At a Glance

Live from database

1FDA treatments

Regulatory Watchboard

No FDA or trial events recorded yet for De novo thrombotic microangiopathy after kidney transplantation.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for De novo thrombotic microangiopathy after kidney transplantation.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

XARELTO

(RIVAROXABAN)standard

Janssen Pharmaceuticals, Inc.

Factor Xa Inhibitor [EPC]

12.1 Mechanism of Action XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban...

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for De novo thrombotic microangiopathy after kidney transplantation.
Search all trials →

Search clinical trials for De novo thrombotic microangiopathy after kidney transplantation →

Recent News & Research

No recent news articles indexed yet for De novo thrombotic microangiopathy after kidney transplantation.
Search PubMed for De novo thrombotic microangiopathy after kidney transplantation →

Browse all De novo thrombotic microangiopathy after kidney transplantation news →

Specialist Network

No specialists currently listed for De novo thrombotic microangiopathy after kidney transplantation.

View all De novo thrombotic microangiopathy after kidney transplantation specialists →

Quick Actions

View Disease Page

Full profile, treatments, community

Search Clinical Trials

Find recruiting studies now

Find Specialists

Ranked by expertise & trials

Financial Assistance

Copay cards, PAPs, grants

Latest News

Research, approvals & updates

Browse All Diseases

11,000+ rare disease profiles